Loading...
Market
How many countries will approve Wegovy for COVID-19 treatment by June 30, 2025?
2
Resolution / Starting Odds
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Official health department announcements from respective countries
Story
Novo Nordisk's Wegovy Cuts COVID-19 Deaths by 33%, Lowers Heart Failure Risks
Aug 30, 2024, 12:00 PM
Recent studies have shown that Novo Nordisk's obesity drug Wegovy, which contains the active ingredient semaglutide, significantly reduces the risk of severe complications and mortality in patients with heart failure and COVID-19. A new analysis found that Wegovy cut the chances of patients dying from COVID-19 by roughly a third compared to placebo, with people taking the drug being 33% less likely to die of COVID-19. Additionally, semaglutide was shown to reduce the risk of heart failure events and cardiovascular death by up to 29% in diabetic patients. These findings were supported by a pooled analysis of four trials, which demonstrated a reduction in emergency hospitalization visits and a composite endpoint including cardiovascular death. The research highlights the potential of Wegovy to bolster the immune system and improve outcomes in patients with obesity and related health conditions.
View original story
Similar markets
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Ban the drugs • 25%
Issue safety warnings • 25%
No action taken • 25%
Other actions • 25%
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
Yes • 50%
No • 50%
Less than 20 • 25%
20 to 40 • 25%
40 to 60 • 25%
More than 60 • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%